Breadcrumb

What's New at the RI-MUHC ?

A clear picture of the cost and efficacy of COVID-19 outpatient treatments

In a new study, RI-MUHC researchers have assessed all available outpatient therapies for COVID-19 to facilitate...

Unraveling the complexity of vitamin B12 diseases

Nature Communications study has implications for treatment of patients and genetic counselling

A new understanding of mental illness

Three key factors might offer 90% accuracy in predicting wide range of psychiatric disorders

$2M to the MUHC Foundation for precision cancer care

BMO gift will help cancer researchers at the RI-MUHC develop the hospital’s precision oncology program

McGill team’s index predicts coma recovery with 100% accuracy

New Adaptive Reconfiguration Index has crucial implications for clinical management and decision-making in unconscious and unresponsive...

RI-MUHC research team leads new consortium to make healthcare data more accessible

The new Quebec SmartCare Consortium has received $10M to break down data silos and increase the...

FANCI: a new gene at the origin of some cases of ovarian cancer

For the first time, researchers link mutations in the FANCI gene to the risk of developing ovarian cancer

Promising COVID-19 therapeutic drug to start phase 3 clinical trial in the United States

Recruitment of first U.S.-based patients in dapsone trial has started

Learn more about the RI-MUHC